NexGel Q2 revenue $1.17M (+108% YoY), net loss improved to $0.13/sh

NEXGEL, INC.

2023-Q2 EPS reported -$0.27 revenue$1,786,000

Revenue $1.17M (+108% YoY), exceeding projections; contract manufacturing +174% YoY.
Net loss improved to $687k ($0.13/sh) from $1M loss ($0.19/sh) in Q2 2022.
Gross profit $175k (15% margin) vs $101k (18%) in prior-year quarter.
Cash and equivalents $4.3M as of March 31, 2023; invested in inventory and capex for H2 demand.
New JV with C.G. Laboratories, strategic relationship with Enigma Health, and new supply agreement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEXGEL, INC. reported the quarter ended June 30, 2023 results: revenue $1.17 million, net income $687 thousand or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.

Period: the quarter ended June 30, 2023
Revenue: $1.17 million
Net income: $687 thousand or $0.13 per basic and diluted share
EPS: $0.13 per basic and diluted share
Result: reported results

Exact text from the filing

For the second quarter of 2023, revenue totaled $1.17 million, an increase of $606 thousand or 108%, as compared to $561 thousand for the same period the year prior.

View on SEC.gov

Browse all earnings releases →

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-028683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.